View in EDS PDF Full Text

Seguridad de la vacuna contra SARS-CoV-2 en pacientes con antecedentes de Síndrome Inflamatorio Multisistémico (SIM-C).

Saved in:
Bibliographic Details
Title: Seguridad de la vacuna contra SARS-CoV-2 en pacientes con antecedentes de Síndrome Inflamatorio Multisistémico (SIM-C).
Alternate Title: Safety of SARS-CoV-2 vaccine in children with a history of Multisystem Inflammatory Syndrome (MIS-C).
Authors: Saravia Herrera, Karina1,2 karina.saravia@ug.uchile.cl, Hojman Jiménez, Josefa1,2, Troncoso Bichara, Javier, Izquierdo Copiz, Giannina1,2, Piñera Morel, Cecilia1,2, Leal Aranda, Paula2, Villena Martínez, Rodolfo1,2
Source: Andes Pediatrica. Dec2024, Vol. 95 Issue 6, p703-710. 14p.
Subjects: MULTISYSTEM inflammatory syndrome, COVID-19 vaccines, HOSPITAL admission & discharge, CHILD patients, COVID-19
Abstract (English): In May 2020, the WHO warned of the occurrence of a multisystem inflammatory syndrome associated with COVID-19 infection (MIS-C) in the pediatric population. Objective: To determine the safety of the SARS-CoV-2 vaccine in Chilean children previously hospitalized due to MIS-C. Patients and Method: Descriptive study on patients with history of MIS-C, discharged from the Hospital Dr. Exequiel González Cortéz in Santiago, Chile, between March 2020 and December 2022 who later received the SARS-CoV-2 vaccine. The number of doses, date of each vaccination, time interval to diagnosis of MIS-C, and the type of vaccine received in the period studied were reviewed. A questionnaire was administered on symptoms and adverse events presented by patients in the period up to 12 weeks after each vaccination, as well as symptoms suggestive of recurrence of MIS-C. Patients who could not be contacted, did not want to participate, or were not susceptible to vaccination were excluded. Results: 50 patients were included, the median age was 5.2 years, 58% were male, and 68% required PICU admission. 82% received at least 1 dose of a SARS-CoV-2 vaccine. The time (median) between MIS-C diagnosis and the first dose of the SARS-CoV-2 vaccine was 15 months (0-24). No serious adverse events or recurrence of MIS-C were reported. Conclusion: Vaccination against SARS-CoV-2 was safe, regardless of age, clinical manifestation of MIS-C, course, type of vaccine, and interval between illness and vaccination. Thereby, the interval for vaccination after MIS-C could be less than 3 months. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): En mayo de 2020 la OMS alertó de la ocurrencia de un síndrome inflamatorio multisistémico asociado a la infección por COVID-19 en población pediátrica. Objetivo: Determinar la seguridad de la vacuna contra SARS-CoV-2 en pacientes pediátricos que previamente han sido hospitalizados por síndrome inflamatorio multisistémico asociado a COVID-19 (SIM-C). Pacientes y Método: Estudio descriptivo en pacientes con diagnóstico de SIM-C egresados del Hospital Dr. Exequiel González Cortés, Santiago, Chile, entre marzo de 2020 y diciembre de 2022 que posteriormente recibieron vacuna contra SARS-CoV-2. Se revisó número de dosis, fecha de cada vacunación, distancia temporal respecto al diagnóstico de SIM-C y el tipo de vacuna recibida en el periodo estudiado. Se aplicó un cuestionario, sobre síntomas y eventos adversos presentados por los pacientes en el periodo de hasta 12 semanas posterior a cada vacunación, así como síntomas sugerentes de recurrencia de SIM-C. Se excluyeron a pacientes que no fue posible contactar, no quisieron participar o no eran susceptibles de vacunar. Resultados: Se incluyeron 50 pacientes, cuya mediana de edad fue de 5,2 años. De estos el 58% eran del sexo masculino y 68 % requirió ingreso a unidad de paciente crítico. El 82% recibió al menos 1 dosis de vacuna contra SARS-CoV-2. El tiempo (mediana) entre el diagnóstico del SIM-C y la primera dosis de la vacuna fue de 15 meses (0-24). No se informaron eventos adversos graves ni recurrencia de SIM-C. Conclusión: La vacunación contra el SARS-CoV-2 presenta un perfil de seguridad adecuado, independientemente de la edad, manifestación clínica del SIM-C, evolución, tipo de vacuna e intervalo entre la enfermedad y la vacunación. El intervalo para vacunar después de un SIM-C podría ser menor a 3 meses. [ABSTRACT FROM AUTHOR]
Copyright of Andes Pediatrica is the property of Revista Chilena de Pediatria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 183300877
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Seguridad de la vacuna contra SARS-CoV-2 en pacientes con antecedentes de Síndrome Inflamatorio Multisistémico (SIM-C).
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Safety of SARS-CoV-2 vaccine in children with a history of Multisystem Inflammatory Syndrome (MIS-C).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Saravia+Herrera%2C+Karina%22">Saravia Herrera, Karina</searchLink><relatesTo>1,2</relatesTo><i> karina.saravia@ug.uchile.cl</i><br /><searchLink fieldCode="AR" term="%22Hojman+Jiménez%2C+Josefa%22">Hojman Jiménez, Josefa</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Troncoso+Bichara%2C+Javier%22">Troncoso Bichara, Javier</searchLink><br /><searchLink fieldCode="AR" term="%22Izquierdo+Copiz%2C+Giannina%22">Izquierdo Copiz, Giannina</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Piñera+Morel%2C+Cecilia%22">Piñera Morel, Cecilia</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Leal+Aranda%2C+Paula%22">Leal Aranda, Paula</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Villena+Martínez%2C+Rodolfo%22">Villena Martínez, Rodolfo</searchLink><relatesTo>1,2</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Andes+Pediatrica%22">Andes Pediatrica</searchLink>. Dec2024, Vol. 95 Issue 6, p703-710. 14p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22MULTISYSTEM+inflammatory+syndrome%22">MULTISYSTEM inflammatory syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19+vaccines%22">COVID-19 vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22HOSPITAL+admission+%26+discharge%22">HOSPITAL admission & discharge</searchLink><br /><searchLink fieldCode="DE" term="%22CHILD+patients%22">CHILD patients</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: In May 2020, the WHO warned of the occurrence of a multisystem inflammatory syndrome associated with COVID-19 infection (MIS-C) in the pediatric population. Objective: To determine the safety of the SARS-CoV-2 vaccine in Chilean children previously hospitalized due to MIS-C. Patients and Method: Descriptive study on patients with history of MIS-C, discharged from the Hospital Dr. Exequiel González Cortéz in Santiago, Chile, between March 2020 and December 2022 who later received the SARS-CoV-2 vaccine. The number of doses, date of each vaccination, time interval to diagnosis of MIS-C, and the type of vaccine received in the period studied were reviewed. A questionnaire was administered on symptoms and adverse events presented by patients in the period up to 12 weeks after each vaccination, as well as symptoms suggestive of recurrence of MIS-C. Patients who could not be contacted, did not want to participate, or were not susceptible to vaccination were excluded. Results: 50 patients were included, the median age was 5.2 years, 58% were male, and 68% required PICU admission. 82% received at least 1 dose of a SARS-CoV-2 vaccine. The time (median) between MIS-C diagnosis and the first dose of the SARS-CoV-2 vaccine was 15 months (0-24). No serious adverse events or recurrence of MIS-C were reported. Conclusion: Vaccination against SARS-CoV-2 was safe, regardless of age, clinical manifestation of MIS-C, course, type of vaccine, and interval between illness and vaccination. Thereby, the interval for vaccination after MIS-C could be less than 3 months. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: En mayo de 2020 la OMS alertó de la ocurrencia de un síndrome inflamatorio multisistémico asociado a la infección por COVID-19 en población pediátrica. Objetivo: Determinar la seguridad de la vacuna contra SARS-CoV-2 en pacientes pediátricos que previamente han sido hospitalizados por síndrome inflamatorio multisistémico asociado a COVID-19 (SIM-C). Pacientes y Método: Estudio descriptivo en pacientes con diagnóstico de SIM-C egresados del Hospital Dr. Exequiel González Cortés, Santiago, Chile, entre marzo de 2020 y diciembre de 2022 que posteriormente recibieron vacuna contra SARS-CoV-2. Se revisó número de dosis, fecha de cada vacunación, distancia temporal respecto al diagnóstico de SIM-C y el tipo de vacuna recibida en el periodo estudiado. Se aplicó un cuestionario, sobre síntomas y eventos adversos presentados por los pacientes en el periodo de hasta 12 semanas posterior a cada vacunación, así como síntomas sugerentes de recurrencia de SIM-C. Se excluyeron a pacientes que no fue posible contactar, no quisieron participar o no eran susceptibles de vacunar. Resultados: Se incluyeron 50 pacientes, cuya mediana de edad fue de 5,2 años. De estos el 58% eran del sexo masculino y 68 % requirió ingreso a unidad de paciente crítico. El 82% recibió al menos 1 dosis de vacuna contra SARS-CoV-2. El tiempo (mediana) entre el diagnóstico del SIM-C y la primera dosis de la vacuna fue de 15 meses (0-24). No se informaron eventos adversos graves ni recurrencia de SIM-C. Conclusión: La vacunación contra el SARS-CoV-2 presenta un perfil de seguridad adecuado, independientemente de la edad, manifestación clínica del SIM-C, evolución, tipo de vacuna e intervalo entre la enfermedad y la vacunación. El intervalo para vacunar después de un SIM-C podría ser menor a 3 meses. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Andes Pediatrica is the property of Revista Chilena de Pediatria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=183300877
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.32641/andespediatr.v95i6.5177
    Languages:
      – Code: mul
        Text: Multiple languages
    PhysicalDescription:
      Pagination:
        PageCount: 14
        StartPage: 703
    Subjects:
      – SubjectFull: MULTISYSTEM inflammatory syndrome
        Type: general
      – SubjectFull: COVID-19 vaccines
        Type: general
      – SubjectFull: HOSPITAL admission & discharge
        Type: general
      – SubjectFull: CHILD patients
        Type: general
      – SubjectFull: COVID-19
        Type: general
    Titles:
      – TitleFull: Seguridad de la vacuna contra SARS-CoV-2 en pacientes con antecedentes de Síndrome Inflamatorio Multisistémico (SIM-C).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Saravia Herrera, Karina
      – PersonEntity:
          Name:
            NameFull: Hojman Jiménez, Josefa
      – PersonEntity:
          Name:
            NameFull: Troncoso Bichara, Javier
      – PersonEntity:
          Name:
            NameFull: Izquierdo Copiz, Giannina
      – PersonEntity:
          Name:
            NameFull: Piñera Morel, Cecilia
      – PersonEntity:
          Name:
            NameFull: Leal Aranda, Paula
      – PersonEntity:
          Name:
            NameFull: Villena Martínez, Rodolfo
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 24526045
          Numbering:
            – Type: volume
              Value: 95
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Andes Pediatrica
              Type: main
ResultId 1